Lithiumisthemost widelyusedtherapyformanic depressive illness. There is no doubt that it is effective (Georgotas & Gershon, 1979) , but with its widespread usehascome an increasing number ofreported side effects. Of these, possible renaltoxicity hascaused most concern,and includes nephrogenicdiabetes insipidus (Forrest eta!,1974; Padfield eta!,1975) , morphological changesintheform ofcharacteristic tubular lesions (Burrowseta!,1978) , and interstitial nephritis (Hansen eta!,1979) .
We have recently described a young femalewith primary adrenal failure requiring gluco-and mineralo corticoid replacement therapy,who, when taking lithium for a manicâ€"depressiveillness, developed mineralocorticoid resistance, requiring 1.0mg of fludrocortisone to avoid mineralocorticoid deficiency (Stewart et a!, 1987) . It appeared that lithium antagonised the action of the exogenous mineralo corticoid (fludrocortisone) on the distal tubule. This was an interesting observation, firstly becausethere was no evidence of nephrotoxicity in our index case and secondly because most of the endocrinopathy reported inpatients on lithium relates to its ability to inhibit the adenyl cyclase-cAMP second-messenger system (Lazarus,1986) .Fludrocortisone, beinga steroid hormone,is notdependent upon this messenger.
To investigate a possibleinteraction between lithium carbonate and the endogenous mineralo corticoid, aldosterone, we studied the renin angiotensin aldosterone systemina series of manicâ€"depressive patients taking lithium prophylactically.
Method
Sixteen patients (five male), maintained on long-term lithium prophylaxis and on no other drugs for a mean of 6.3years (range 0.5â€"18 years), werecompared with16age and sex-matched normalcontrol subjects. Clinically, the control subjects wereingood health, withno history of psychiatric disorder. The patients attended on an out-patient basis and,having omitted their morningdoseoflithium, lay supine for a minimum of 30 mm commencing at 0830 h.
Blood pressure was measured automatically using a Copal electronic sphygmomanometer (Rademaker eta!, 1987 )the mean of three readings in the supine position being recorded. Erect blood pressure was measured after standing for 1 mm.
After 30mm supine, bloodwastaken on ice forplasma remnactivity (PRA), plasma aldosterone (aldo), creatinine, electrolytes, and serum lithium levels. Specimens for PRA and aldo were spun at 2000g for 15mm at 4Â°C,and plasma aliquoted and stored at â€"¿ 20 Â°C. PRA was measured by radioimmunoassay using a modification ofthemethodof Haber et a! (1969) ; aldowas measuredby thedirect radioimmunoassay of Al-Dujaili & Edwards (1981) . To exclude a direct effect of lithium in the aldosterone assay, aliquots of plasma samples from eight patients on lithium wereextracted with 5 volumes ofdichloromethane, andthe extract washedwith0.1M NaOH andwithwater. Aliquots of extract of equalvolumetotheoriginal plasmawere evaporated to dryness under nitrogen and assayed. Lithium carbonate was added to further duplicate aliquots of extracted plasma in a concentration of 6 nmol litre -I and these samples assayed as before. Creatinine and electrolyte levelswere measured by an ion-selectivemethod, and serum lithium measured by flame photometry.
Analysis of our results revealed a normal distribution; comparisons between the two groups were therefore made using Student's unpaired t-test, correlations using Pearson's test.
Results
The mean age of the 16 patients on lithium was 46Â±17 (s.d.)
years, that ofcontrol subjects 45Â± 14years. Serumlithium concentrations were in the therapeutic range of 0.7-1.2 mmol litre@ at 0.78Â±0.l7mmol litre@ (mean Â±s.d. Plasma renin activity (PRA), aldosterone (aldo) levels, electrolyte levels, and blood pressures were measured in 16 patients with affective disorders taking lithium prophy lactically, and in 16 age and sex-matched control subjects. PRA and aldo levels were significantly elevatedinthe lithium-treated group.There was no difference between the groups in plasma electrolytes or erect and supine blood pressures,arguing against secondary aldosteronism.
In the lithium-treated group, there was a significant positive correlation between both PRA and plasma aldo vs serum lithium. We postulate that lithium inhibits the actionofaldosterone on the distal tubuleinthe kidney.Activation ofthe renin angiotensinsystem maintainsnormal blood pressureand plasma electrolytes. Therewas no significant difference inbloodpressure betweenthecontrol and lithium-treated groups[mean supine bloodpressure 90.2Â± 16.6vs95.1 Â±17.1 mm Hg respectively (mean Â± s.d.)]. Similarly, both groups showeda similar rise inbloodpressure on adopting the erect posture (mean erect blood pressure 97.6 Â± 16.9 vs 102.5 Â±18.2 mm Hg).
One subject was excluded fromthestudy because his serumlithium concentration indicated he didnottake lithium regularly. His PRA at 0.6 ng ml h and aldo at 500 pmol litre' were similar to control values. In six patients on lithium, Na@ andK@ excretion wasestimated from a 24-hurine collection. Althoughdietary intake was not assessed, mean 24-hurineNa@ excretion at 117Â±31 mmol litre-' (Â±s.d.) and urinary NaVK@ ratio at2.8(range 2.1â€"3.3) arguedagainst mineralocorticoid excess suchasmay occurinvolumedepletion.
Discussion
We haveshown activation oftherenin-angiotensin aldosterone system in a group of patients with affective disorders taking long-term lithium carbonate.
Plasma renin activity and aldosterone levels are significantly elevated when compared witha healthy age and sex-matchedcontrolgroup.The absence of postural hypotension, similar plasma creatinines and, above all, similar plasma potassium in the two groups argues against secondary aldosteronism as may occur in hypovolaemia caused by sodium depletion. In 1969, Murphy et a! showed that patients given lithium carbonate had an initial natriuresis lasting for the first 48 h, followed by sodium retention lasting for up to 5 days associated with a 50% increase in aldosterone secretion. However, by 14 days, all subjects studied were in balance with pre treatment aldosterone levels. Only two other studies have looked at aldosterone levels in patients on lithium, but not intoxicated (Pedersen eta!,1977; Transbol et a!, 1978) . Surprisingly, Pedersen et a! (1977) found no difference in aldosterone levels in their treated group, and we are unable to explain this discrepancy with our study. However, there was a positive correlation between plasma aldosterone and serum lithium(r=0.52, n = 27, P<0.01) as we observed. Transbol eta! (1978) did report elevation of both PRA and aldosterone in some patients on maintainance lithium, albeit in a poorly controlled study.
Apart from our one subject who was not taking lithium, it was not possible to study a psychiatric control group, since there were no patients who fell into one of the psychiatric categories described above but were taking no medication. There are previous reports of elevated aldosterone levels in mania, and reduced levels in depression (Allsopp classified according totheResearch Diagnostic Criteria (Spitzer eta!,1978 (Hendler, 1975) .
Ina smallnumber of patients, spironolactone (an aldosterone antagonist) was shown to have a beneficial effect in manic-depressive patients, which the authors argued may not be surprising in view of the opposing action of lithium and aldosterone on adenyl cyclase (Hendler, 1978; Oilman & Lichtigeld, 1986) . This has led these workers to suggest an aetiological role for aldosterone in manic-depressive illness.
In animal models, several studies have suggested mineralocorticoid blockade in rats pre-treated with lithium (Gutman eta!, 1973 , Baer eta!, 1973 , Thomson eta!,1976 . Having documented mineralocorticoid resistance to the exogenous mineralocorticoid, fludro cortisone, in man (Stewart et a!, 1987) , we now postulate that lithium induces a state of mineralo corticoid resistance by inhibiting the action of aldosterone on the distal tubule in the kidney. Compensatory activation of the renin-angiotensin aldosterone axis maintains normal blood pressure and plasma electrolytes.
